written on 11.03.2014
Tags:
,

5 burning questions for an orphan drug CEO

TAGS: ,

Resistance will be there, but this is no different than for high volume drugs; it is about the impact and value of the treatment provided. It should also be noted that HTA (Health Technology Assessment) tools will often not work in small disease…

Latest Report